Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic HB-adMSCs
- Development stage
- Phase 2
- Lead developer
- Hope Biosciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
Allogeneic HB-adMSCs are a cell therapy product consisting of culture-expanded, adipose-derived mesenchymal stem cells (MSCs) developed by Hope Biosciences. Unlike autologous treatments, these cells are sourced from healthy donors and manufactured using a proprietary, standardized cell culture process designed to produce high volumes of consistent, repeatable MSCs. The therapy leverages the immunomodulatory and regenerative properties of MSCs, which migrate to sites of injury or inflammation to secrete bioactive molecules that inhibit inflammatory processes and promote tissue repair. It is currently being evaluated in clinical trials for a variety of conditions, including traumatic and nontraumatic brain injury, Multiple System Atrophy, Crohn's disease, and COVID-19.
- Other names
- allogeneic Hope Biosciences adipose-derived mesenchymal stem cellsallogeneic adipose-derived mesenchymal stromal cellsallogeneic HB-adMSC
Beyond the preview
Go deeper on allogeneic HB-adMSCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic HB-adMSCs.